Vaxess Raises Additional $10M in Funding
Summary
Vaxess, a Cambridge, MA-based life sciences company developing a shelf-stable vaccine patch with potential for self-application, raised additional $10M in funding. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness. Engineered for stability, its patch does not require refrigeration and can be shipped to and applied in low resource settings. In December, Vaxess published the initial results from its phase 1 trial of the MIMIX-Flu vaccine patch. The trial, conducted in 45 healthy patients, evaluated H1N1 influenza antigen from Vaxess’s partner, GC Biopharma Corp., delivered via the MIMIX Patch.
Funding
Review available funding amount, funding date, investors, and linked company information related to Vaxess Raises Additional $10M in Funding in the interactive ISVWorld profile.